---
title: "Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288476320.md"
description: "Vertex Pharmaceuticals (VRTX) shares fell 3.04% to $425.09 on Tuesday, underperforming the broader market and competitors like AbbVie despite a positive trading session. This marks the third consecutive day of losses for VRTX, which is now 16.31% below its 52-week high. Trading volume remained below the 50-day average."
datetime: "2026-06-02T20:38:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288476320.md)
  - [en](https://longbridge.com/en/news/288476320.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288476320.md)
---

# Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Vertex Pharmaceuticals Inc. (VRTX) slid 3.04% to $425.09 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.13% to 7,609.78 and the Dow Jones Industrial Average rising 0.45% to 51,307.79.

This was the stock's third consecutive day of losses.

Vertex Pharmaceuticals Inc. closed 16.31% below its 52-week high of $507.92, which the company achieved on March 10th.

The stock underperformed when compared to some of its competitors Tuesday, as AbbVie Inc. (ABBV) rose 1.16% to $215.40, Krystal Biotech Inc. (KRYS) fell 1.64% to $293.21, and Arcturus Therapeutics Holdings Inc. (ARCT) fell 1.54% to $7.65.

Trading volume (1.1 M) remained 104,626 below its 50-day average volume of 1.2 M.

Data source: Dow Jones Market Data, FactSet. Data compiled June 2, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

06-02-26 1638ET

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [ABBV.US](https://longbridge.com/en/quote/ABBV.US.md)
- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)
- [ARCT.US](https://longbridge.com/en/quote/ARCT.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference | VRTX Stock News](https://longbridge.com/en/news/288887349.md)
- [Vertex Pharmaceuticals Stock: Is VRTX Underperforming the Healthcare Sector?](https://longbridge.com/en/news/288312641.md)
- [Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 | VRTX Stock News](https://longbridge.com/en/news/288621138.md)
- [UMH PROPERTIES, INC. PUBLISHES ITS 2025 SUSTAINABILITY REPORT | UMH Stock News](https://longbridge.com/en/news/289078379.md)
- [Vertex Extends Cystic Fibrosis Reach With Pediatric ALYFTREK And TRIKAFTA Data](https://longbridge.com/en/news/289199131.md)